EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Von Willebrand Disease Type 2A: An Update

Omid Seidizadeh iD, Luciano Baronciani iD, Pier Mannuccio Mannucci iD, Flora Peyvandi iD

Seminars in Thrombosis and Hemostasis · 01.09.2026 · 52 (06) · 618-627

DOI: 10.1055/a-2778-9989 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Thrombosis and Hemostasis, erschienen am 01.09.2026. Verfasst von Omid Seidizadeh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, …. Hauptthemen laut MEDLINE: von Willebrand Disease, Type 2, von Willebrand Factor. Die Arbeit nennt 84 Literaturangaben. Gefördert von: Italian Ministry of Health, Bando Ricerca Corrente.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dysfunctional or quantitatively deficient von Willebrand factor (VWF) underlies von Willebrand disease (VWD), the most common inherited bleeding disorder. Type 2A VWD is a qualitative defect marked by impaired VWF-dependent platelet adhesion, typically reflected in disproportionately reduced ratios of platelet-dependent VWF activity to antigen (VWF activity/VWF:Ag) and collagen binding to antigen (VWF:CB/VWF:Ag). This phenotype results from a selective reduction or lack of high- and intermediate-molecular-weight multimers, which are essential for effective hemostasis under high shear stress. The lack of multimer arises from impaired multimer assembly and/or increased proteolytic cleavage of VWF by ADAMTS13. Clinically, type 2A tends to present with greater severity than other type 2 variants, manifesting as mucocutaneous bleeding, often including heavy menstrual bleeding, epistaxis, post-surgical bleeding and gastrointestinal hemorrhage from angiodysplasia. Diagnosis relies on functional assays and VWF multimer analysis, supported by genetic testing that identifies subtype-specific mutations affecting VWF multimeric structure and therefore its function. Type 2A is typically inherited in an autosomal dominant manner, with rare exceptions of autosomal recessive inheritance. Structural and molecular studies are continuing to elucidate how domain-specific variants disrupt multimeric structure and thus interactions with its ligands. Management is guided by bleeding severity and includes desmopressin (following responsiveness testing) and VWF replacement therapy. This review provides an in-depth update on type 2A VWD, covering its epidemiology, pathophysiology across distinct subtypes, clinical manifestations, diagnostic approach, molecular and structural insights, and current therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

von Willebrand Disease, Type 2von Willebrand FactorHumans

Substanzen

von Willebrand Factor

Autor:innen und Institutionen

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy.
  • Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.

ORCID-Profile: Omid Seidizadeh, Luciano Baronciani, Pier Mannuccio Mannucci, Flora Peyvandi

Förderung

  • Italian Ministry of Health, Bando Ricerca Corrente

Zitieren

APA

Seidizadeh, O., Baronciani, L., Mannucci, P. M., & Peyvandi, F. (2026). Von Willebrand Disease Type 2A: An Update. Seminars in Thrombosis and Hemostasis, 52(06), 618-627. https://doi.org/10.1055/a-2778-9989

Vancouver

Seidizadeh O, Baronciani L, Mannucci PM, Peyvandi F. Von Willebrand Disease Type 2A: An Update. Seminars in Thrombosis and Hemostasis. 2026;52(06):618-627. doi:10.1055/a-2778-9989

BibTeX
@article{Seidizadeh2026,
  author = {Seidizadeh, Omid and Baronciani, Luciano and Mannucci, Pier Mannuccio and Peyvandi, Flora},
  title = {Von Willebrand Disease Type 2A: An Update},
  journal = {Seminars in Thrombosis and Hemostasis},
  year = {2026},
  volume = {52},
  number = {06},
  pages = {618--627},
  doi = {10.1055/a-2778-9989}
}
Kostenlos starten →